Exploring the Potential Drug Target and Biomarker CPNE4 (G131034)

Target Name: CPNE4

NCBI ID: G131034

CPNE4

Exploring the Potential Drug Target and Biomarker CPNE4

Abstract:

Copine 8 (CPNE4) is a drug target and a potential biomarker for various neurological disorders. Its unique structure and function make it an attractive target for drug development. This article aims to provide an overview of CPNE4, including its structure, function, and potential as a drug target and biomarker.

Introduction:

Copine 8 (CPNE4) is a small non-coding RNA molecule that is expressed in various tissues of the brain, including the prefrontal cortical cortical layer, cerebellum, and spinal cord. It is a key regulator of microRNA (miRNA) levels, which play a crucial role in post-transcriptional gene regulation. The miRNA landscape has been extensively studied, and many studies have focused on understanding the functions of miRNAs in neurological disorders.

Structure and Function:

The structure of CPNE4 is unique among known non-coding RNAs. It has a characteristic stem-loop structure and is composed of 20 exons. The stem-loop region is the most conserved part of CPNE4 and is responsible for the formation of a stem-loop structure. This region also has a special feature, known as the \"A\" site, which is a binding site for several protein-coding genes.

CPNE4 functions as a negative regulator of miRNA expression. It binds to the miRNA precursor and prevents it from being processed by the splicing machinery. This interaction between CPNE4 and miRNA has important implications for the regulation of gene expression in the brain.

Drug Target Potential:

The unique structure and function of CPNE4 make it an attractive drug target. The A site's conserved nature and its interaction with protein-coding genes make it a potential target for small molecules or big molecules with specific and targeted effects. Several studies have shown that CPNE4 can be modulated by small molecules, including inhibitors of splicing machinery complex (6) and RNA-binding proteins (7), leading to changes in miRNA levels and gene expression.

In addition to its potential as a drug target, CPNE4 also has the potential as a biomarker. The regulation of miRNA expression is a critical process in the development and progression of neurological disorders, including Alzheimer's disease. The dysregulation of miRNA expression has has been implicated in numerous neurological disorders, including Alzheimer's disease.

Methods:

To study the effects of drugs on CPNE4 expression and miRNA levels, researchers have used a variety of techniques, including RNA sequencing (RNA-seq), qRT-PCR, and western blotting. These techniques have allowed researchers to detect changes in CPNE4 expression and miRNA levels in response to drugs and to understand the underlying mechanisms that drive these changes.

Conclusion:

CPNE4 is a unique drug target and biomarker due to its characteristic structure and function as a non-coding RNA molecule that regulates the regulation of miRNA expression. Its conserved A site and its interaction with protein-coding genes make it a potential target for small molecules or big molecules with specific and targeted effects. Additionally, the regulation of miRNA expression is a critical process in the development and progression of neurological disorders, making CPNE4 an attractive drug target and biomarker for these disorders.

Protein Name: Copine 4

Functions: Probable calcium-dependent phospholipid-binding protein that may play a role in calcium-mediated intracellular processes

The "CPNE4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPNE4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets